correlational
Analysis v1
49
0
People with type 2 diabetes who take SGLT-2 inhibitors tend to have lower levels of a key inflammation marker called interleukin-6 than those taking other diabetes medications.
Scientific Claim
In patients with type 2 diabetes, SGLT-2 inhibitor use is associated with lower circulating interleukin-6 levels compared to other glucose-lowering drugs (n=43 per group, p < 0.05).
Original Statement
“Patients treated with SGLT-2i had lower circulating levels of IL-6, a prototypical marker of LGI, but also of uric acid and fasting insulin, compared with patients treated with other GLD.”
Evidence Quality Assessment
Claim Status
appropriately stated
Study Design Support
Design supports claim
Appropriate Language Strength
association
Can only show association/correlation
Assessment Explanation
Observational study design can only establish association, not causation. 'Associated with' correctly reflects the evidence.
Evidence from Studies
Supporting (1)
49
49
Anti-inflammatory effect of SGLT-2 inhibitors via uric acid and insulin
Cross-Sectional Study
Human
2022 May 3Contradicting (0)
0
No contradicting evidence found